 Ticlopidine
"Ticlopidine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Ticlopidine is an effective inhibitor of platelet aggregation. The drug has been found to significantly reduce infarction size in acute myocardial infarcts and is an effective antithrombotic agent in arteriovenous fistulas, aorto-coronary bypass grafts, ischemic heart disease, venous thrombosis, and arteriosclerosis.
| Descriptor ID |
D013988
|
| MeSH Number(s) |
D02.886.778.823.500 D03.383.725.849.500 D03.383.903.830.500 D03.438.928.500
|
| Concept/Terms |
Ticlodix- Ticlodix
- Vitoria Brand of Ticlopidine Hydrochloride
Ticlodone- Ticlodone
- Almirall Brand of Ticlopidine Hydrochloride
Ticlid- Ticlid
- Roche Brand of Ticlopidine Hydrochloride
|
Below are MeSH descriptors whose meaning is more general than "Ticlopidine".
Below are MeSH descriptors whose meaning is more specific than "Ticlopidine".
This graph shows the total number of publications written about "Ticlopidine" by people in UAMS Profiles by year, and whether "Ticlopidine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2016 | 3 | 1 | 4 | | 2015 | 5 | 1 | 6 | | 2014 | 2 | 0 | 2 | | 2013 | 2 | 3 | 5 | | 2012 | 2 | 2 | 4 | | 2010 | 1 | 0 | 1 | | 2009 | 3 | 1 | 4 | | 2006 | 1 | 0 | 1 | | 2005 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Ticlopidine" by people in Profiles over the past ten years.
-
Jain N, Corken A, Arthur JM, Ware J, Arulprakash N, Dai J, Phadnis MA, Davis O, Rahmatallah Y, Mehta JL, Hedayati SS, Smyth S. Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease. Vascul Pharmacol. 2023 02; 148:107143.
-
Hernandez-Suarez DF, N??ez-Medina H, Scott SA, Lopez-Candales A, Wiley JM, Garcia MJ, Melin K, Nieves-Borrero K, Rodriguez-Ruiz C, Marshall L, Duconge J. Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. Drug Metab Pers Ther. 2018 03 28; 33(1):49-55.
-
Hernandez-Suarez DF, Scott SA, Tomey MI, Melin K, Lopez-Candales A, Buckley CE, Duconge J. Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. Ther Adv Cardiovasc Dis. 2017 Sep; 11(9):235-241.
-
Nairooz R, Valgimigli M, Rochlani Y, Pothineni NV, Raina S, Sardar P, Mukherjee D, Naidu SS, Shavelle DM. Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. Int J Cardiol. 2017 Feb 15; 229:82-89.
-
Brice AE, Hernandez GA, Sanchez M, Haynick M, Mendoza CE. In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention. Platelets. 2017 May; 28(3):305-309.
-
Meena N, Abouzgheib W, Patolia S, Rosenheck J, Boujaoude Z, Bartter T. EBUS-TBNA and EUS-FNA: Risk Assessment for Patients Receiving Clopidogrel. J Bronchology Interv Pulmonol. 2016 Oct; 23(4):303-307.
-
Jain N, Reilly RF. Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current?Knowledge and Future Directions. Semin Dial. 2016 09; 29(5):374-81.
-
Jain N, Li X, Adams-Huet B, Sarode R, Toto RD, Banerjee S, Hedayati SS. Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease. Am J Cardiol. 2016 Feb 15; 117(4):656-663.
-
Trindade AJ, Hirten R, Slattery E, Inamdar S, Sejpal DV. Endoscopic ultrasound-guided fine-needle aspiration of solid lesions on clopidogrel may not be a high-risk procedure for bleeding: A case series. Dig Endosc. 2016 Mar; 28(2):216-9.
-
Hoh BL, Gong Y, McDonough CW, Waters MF, Royster AJ, Sheehan TO, Burkley B, Langaee TY, Mocco J, Zuckerman SL, Mummareddy N, Stephens ML, Ingram C, Shaffer CM, Denny JC, Brilliant MH, Kitchner TE, Linneman JG, Roden DM, Johnson JA. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. J Neurosurg. 2016 Jun; 124(6):1746-51.
-
Nairooz R, Ayoub K, Shavelle D. Duration of Triple Therapy: A Clinical Question Yet to Be Answered. J Am Coll Cardiol. 2015 Nov 17; 66(20):2266.
-
Beavers CJ, Heron P, Smyth SS, Bain JA, Macaulay TE. Obesity and Antiplatelets-Does One Size Fit All? Thromb Res. 2015 Oct; 136(4):712-6.
-
Ayoub K, Marji M, Nairooz R. Antithrombotic and Antiplatelet Therapy in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention. Am J Cardiol. 2015 Sep 01; 116(5):828-9.
-
Azzalini L, Al-Hawwas M, L'Allier PL. Very late bioresorbable vascular scaffold thrombosis: a new clinical entity. EuroIntervention. 2015 May 19; 11(1):e1-2.
-
Sardar P, Nairooz R, Pekler G. Letter by Sardar et al regarding article, "optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial". Circulation. 2014 Oct 28; 130(18):e160.
-
Lecka J, Fausther M, K?nzli B, S?vigny J. Ticlopidine in its prodrug form is a selective inhibitor of human NTPDase1. Mediators Inflamm. 2014; 2014:547480.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|